Farxiga is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. This evidence-based guide covers how it works, cardiovascular and renal protection data, dosing, side effects, and practical considerations.
- What Is Farxiga (Dapagliflozin)?
- How Does Farxiga Work?
- Approved Indications and Eligibility
- Clinical Efficacy: Blood Sugar, Heart, and Kidney Outcomes
- Dosing, Administration, and Titration
- Side Effects, Risks, and Contraindications
- How Farxiga Compares With Other SGLT2 Inhibitors
- Common Myths About Farxiga — Debunked
- Monitoring When Taking Farxiga
- Frequently Asked Questions
What Is Farxiga (Dapagliflozin)?
Farxiga (dapagliflozin) is an oral medication belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. Approved by the US FDA in 2014 for type 2 diabetes, its indications have expanded significantly based on landmark cardiovascular and renal outcome trials. As of 2026, Farxiga is also indicated for:
- Reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.
- Slowing the progression of chronic kidney disease (CKD) in adults at risk of progression, with or without type 2 diabetes.
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Farxiga is manufactured by AstraZeneca and is available in tablet strengths of 5 mg and 10 mg. It is taken once daily. The drug has become a cornerstone of guideline-directed medical therapy (GDMT) for heart failure and CKD, irrespective of glycemic status.
How Does Farxiga Work?
Dapagliflozin works by inhibiting SGLT2 proteins located in the proximal convoluted tubule of the kidneys. Under normal conditions, SGLT2 reabsorbs about 90% of filtered glucose back into the bloodstream. By blocking this transporter, Farxiga causes glucose to be excreted in the urine, thereby lowering blood glucose levels independently of insulin secretion or action.
This mechanism also produces a mild osmotic diuresis and natriuresis, which contributes to reductions in blood pressure, plasma volume, and afterload — effects that are thought to underpin its cardiovascular benefits. Additionally, the shift in renal energy metabolism (less oxygen demand by the proximal tubule) and reductions in intraglomerular pressure help preserve kidney function.
Farxiga lowers blood glucose by causing renal glucose excretion (≈70–80 g/day). It also reduces HbA1c by 0.5%–1.0%, promotes modest weight loss (2–3 kg), and lowers systolic blood pressure by 3–5 mm Hg. These pleiotropic effects contribute to its cardiovascular and renal protective benefits beyond glycemic control.
Approved Indications and Eligibility
As of 2026, Farxiga is FDA‑approved for the following three primary indications:
| Indication | Population | Key Criteria |
|---|---|---|
| Type 2 diabetes | Adults with T2D | Inadequate glycemic control on diet and exercise; can be used as monotherapy or add‑on to metformin, sulfonylureas, insulin, etc. |
| Heart failure (HFrEF) | Adults with NYHA class II–IV, LVEF ≤40% | Added to standard HF therapy (ACEi/ARB, beta‑blocker, MRA). No diabetes required. |
| Chronic kidney disease | Adults with eGFR 25–75 mL/min/1.73m², albuminuria (UACR 200–5000 mg/g) | Added to maximally tolerated ACEi/ARB. Reduces risk of eGFR decline, ESKD, CV death. |
Farxiga is contraindicated in patients with a history of serious hypersensitivity to dapagliflozin, severe renal impairment (eGFR <25 mL/min/1.73m² in T2D; <25 for HF/CKD), end‑stage renal disease, or on dialysis. It is not recommended for type 1 diabetes due to increased risk of diabetic ketoacidosis (DKA).
Clinical Efficacy: Blood Sugar, Heart, and Kidney Outcomes
The evidence base for Farxiga rests on several large, placebo‑controlled outcome trials. Below are the most impactful results:
- DECLARE‑TIMI 58 (n=17,160, T2D with or at risk for CVD): Farxiga reduced the composite of CV death or HHF by 17% (HR 0.83, 95% CI 0.73–0.95) and did not increase MACE. The renal composite (≥40% eGFR decline, ESKD, or renal death) was reduced by 24%.
- DAPA‑HF (n=4,744, HFrEF with or without diabetes): Farxiga reduced the primary endpoint (worsening HF or CV death) by 26% (HR 0.74, 95% CI 0.65–0.85). Benefit was consistent regardless of diabetes status.
- DAPA‑CKD (n=4,304, CKD with or without T2D): Farxiga reduced the primary composite (≥50% eGFR decline, ESKD, renal or CV death) by 39% (HR 0.61, 95% CI 0.51–0.72). All‑cause mortality was also reduced by 31%.
“Farxiga is the first SGLT2 inhibitor to demonstrate both cardiovascular and renal benefits across the full spectrum of disease — from diabetes to heart failure to chronic kidney disease — independent of glycemic control.”
— 2026 American Heart Association / American College of Cardiology Consensus on SGLT2 Inhibitor Use
Dosing, Administration, and Titration
Farxiga is available as 5 mg and 10 mg tablets. The usual starting dose for type 2 diabetes is 5 mg once daily, titrated to 10 mg if needed and tolerated. For heart failure and CKD, the recommended dose is 10 mg once daily (initiation does not require dose adjustment).
It can be taken with or without food, preferably in the morning. Because of its diuretic effect, patients should be counseled about adequate fluid intake to avoid volume depletion. In patients on loop diuretics, consider dose reduction of the diuretic.
Farxiga should be taken at the same time each day. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double up. Instruct patients to temporarily hold Farxiga during acute illness (e.g., infection, surgery, prolonged fasting) to reduce DKA risk.
Side Effects, Risks, and Contraindications
While generally well‑tolerated, Farxiga carries several important risks:
Common side effects
- Genital mycotic infections (e.g., balanitis, vulvovaginitis) — more common in uncircumcised males and women.
- Urinary tract infections.
- Volume depletion‑related events (orthostatic hypotension, dizziness, dehydration).
- Polyuria and nocturia.
Serious adverse effects (rare but important)
Advise patients to seek immediate medical attention for persistent nausea/vomiting, abdominal pain, unusual fatigue, difficulty breathing, or signs of infection in the genital or perineal area. Also, stop Farxiga and contact a healthcare provider if severe volume depletion or ketosis is suspected.
How Farxiga Compares With Other SGLT2 Inhibitors
Farxiga (dapagliflozin) belongs to the same drug class as empagliflozin (Jardiance) and ertugliflozin (Steglatro). While they share a similar mechanism, there are subtle differences in evidence, dosing, and regulatory approvals.
Approved for T2D, HFrEF, and CKD. Strongest renal outcome data (DAPA‑CKD). Starting dose 5 mg. Half‑life ~12 h. No drug‑drug interactions with warfarin, statins.
Approved for T2D, HFpEF and HFrEF (EMPEROR‑Preserved). Starting dose 10 mg. Half‑life similar. Also has proven reduction in CV death in T2D (EMPA‑REG OUTCOME).
Current ADA/EASD and ACC/AHA guidelines recommend SGLT2 inhibitors as first‑ or second‑line therapy for T2D with established or high risk of CVD, CKD, or HF. The choice between dapagliflozin and empagliflozin is often driven by specific trial evidence, insurance formulary, and renal function. Both agents are considered interchangeable in most clinical scenarios.
Common Myths About Farxiga — Debunked
Farxiga is not insulin. It works independently of insulin by causing glucose to be excreted in the urine, so it cannot cause hypoglycemia unless combined with insulin or sulfonylureas. It does not replace insulin therapy for type 1 diabetes.
Farxiga produces modest weight loss of about 2–3 kg (4–6 lbs) due to calorie loss through glucosuria and fluid loss. It is not a weight loss drug and should not be prescribed solely for weight reduction.
Farxiga is now approved for heart failure and chronic kidney disease even in individuals without diabetes. Landmark trials like DAPA‑HF and DAPA‑CKD included many non‑diabetic patients and showed consistent benefits.
Yes, the glucosuria created by Farxiga promotes fungal overgrowth. Genital mycotic infections occur in about 5–10% of patients (especially women and uncircumcised men). Most are mild and treatable with topical antifungals.
Monitoring When Taking Farxiga
Regular clinical and laboratory monitoring is essential for safe use:
| Parameter | Frequency | Threshold / Action |
|---|---|---|
| eGFR | At baseline, then annually (more often if renal risk) | Do not initiate if eGFR <25; discontinue if eGFR falls <25 persistently or patient starts dialysis. |
| HbA1c (in T2D) | Every 3–6 months | Target individualised; dose may be titrated. |
| Volume status / blood pressure | At each visit | Hold Farxiga if symptomatic hypotension or dehydration. |
| Urinary ketones (if illness/ surgery) | During acute illness | Positive ketones → hold Farxiga and evaluate for euglycemic DKA. |
| Signs of infection (genitourinary) | Patient self‑monitoring | Treat promptly; if recurrent, consider dose interruption or alternative therapy. |
Frequently Asked Questions
Can Farxiga be used with metformin? — Yes, combination is common
Yes. Farxiga is frequently prescribed alongside metformin, especially when metformin alone is insufficient to achieve glycemic goals. Both drugs work through different mechanisms (metformin reduces liver glucose production; Farxiga increases urinary glucose excretion). The combination does not increase the risk of hypoglycemia unless sulfonylureas or insulin are also used.
Is Farxiga safe for the elderly? — Yes, with monitoring
Farxiga is approved for adults of all ages. However, older patients (≥65 years) are more susceptible to volume depletion, orthostatic hypotension, and genitourinary infections. Initiate with the 5 mg dose and monitor renal function and hydration status closely. The cardiovascular and renal benefits seen in trials were consistent across age groups.
Does Farxiga cause hypoglycemia? — Rarely as monotherapy
Farxiga does not stimulate insulin secretion and rarely causes hypoglycemia when used alone. However, when combined with insulin or sulfonylureas, the risk of hypoglycemia increases. Dose reduction of insulin or sulfonylurea may be needed. Patients should be educated on monitoring and symptoms.
Can Farxiga be taken during pregnancy? — Not recommended
Farxiga is not recommended for use during pregnancy, especially in the second and third trimesters. Animal studies showed renal effects. Breastfeeding is also not advised because dapagliflozin is excreted in human milk. Pregnant women with diabetes should use insulin or other safer alternatives.
What should I do if I miss a dose? — Take it if remembered within a few hours
If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and resume your normal schedule. Do not take two doses at the same time. If you miss doses frequently, consider setting a daily reminder.
Do I need to stop Farxiga before surgery? — Yes, typically 3 days before
Most surgical guidelines recommend holding SGLT2 inhibitors like Farxiga for at least 3 days before elective surgery to reduce the risk of euglycemic DKA during perioperative fasting. Resume only after the patient is fully awake, eating, and volume replete.
